https://orcid.org/0000-0001-9690-8555
References
- Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63–70.
- Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): a review of the entity. Semin Diagn Pathol. 1990;7(1):19–73.
- Emile J-F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681.
- Niu YY, Li YJ, Wang J, et al. Laryngeal Rosai–Dorfman disease (Sinus histiocytosis with massive lymphadenopathy): a retrospective study of 5 cases. Biomed Res Int. 2017;2017(1):1–6.
- Cai Y, Shi Z, Bai Y. Review of Rosai–Dorfman disease: new insights into the pathogenesis of this rare disorder. Acta Haematol. 2017;138(1):14–23.
- Harley EH. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease) in a patient with elevated Epstein-Barr virus titers. J Natl Med Assoc. 1991;83(10):922–924.
- Levine PH, Jahan N, Murari P, et al. Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). J Infect Dis. 1992;166(2):291–295.
- Kaur PP, Birbe RC, DeHoratius RJ. Rosai–Dorfman disease in a patient with systemic lupus erythematosus. J Rheumatol. 2005;32(5):951–953.
- Grabczynska SA, Toh CT, Francis N, et al. Rosai–Dorfman disease complicated by autoimmune haemolytic anaemia: a case report and review of a multisystem disease with cutaneous infiltrates. Br J Dermatol. 2001;145(2):323–326.
- Chen TD, Lee LY. Rosai–Dorfman disease presenting in the parotid gland with features of IgG4-related sclerosing disease. Arch Otolaryngol Head Neck Surg. 2011;137(7):705–708.
- Saboo SS, Jagannathan JP, Krajewski KM, et al. Symptomatic extranodal Rosai–Dorfman disease treated with steroids, radiation, and surgery. J Clin Oncol. 2011;29(31):e772–e775.
- Tjiu JW, Hsiao CH, Tsai TF. Cutaneous Rosai–Dorfman disease: remission with thalidomide treatment. Br J Dermatol. 2003;148(5):1060–1061.
- Shahidi-Dadras M, Hamedani B, Niknezhad N, et al. Rosai-Dorfman disease successfully treated with thalidomide: a case report. Dermatol Ther. 2019;32(5):e13005.
- Subramaniyan R, Ramachandran R, Rajangam G, et al. Purely cutaneous Langerhans cell histiocytosis presenting as an ulcer on the chin in an elderly man successfully treated with thalidomide. Indian Dermatol Online J. 2015;6(6):407–409.
- McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48(1):44–49.
- Rubinstein M, Assal A, Scherba M, et al. Lenalidomide in the treatment of Rosai Dorfman disease-a first in use report. Am J Hematol. 2016;91(2): E1.
- Anderson KC. Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol. 2005; 42(4 Suppl 4):S3–S8.
- Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996;35(6):969–979.
- Passeron T, Lacour JP, Murr D, et al. Thalidomide-induced amenorrhoea: two cases. Br J Dermatol. 2001;144(6):1292–1293.
- Ordi J, Cortes F, Martinez N, et al. Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum. 1998;41(12):2273–2275.